Margie R Skeer1, Keren Ladin2, Lindsay E Wilkins3, David M Landy4, Thomas J Stopka5. 1. Tufts University School of Medicine, Department of Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA 02186, USA. Electronic address: Margie.Skeer@tufts.edu. 2. Tufts University, Departments of Occupational Therapy and Community Health, 574 Boston Avenue, Suite 216, Medford, MA 02155, USA. Electronic address: Keren.Ladin@tufts.edu. 3. Tufts University School of Medicine, Department of Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA 02186, USA. Electronic address: Lindsay.Wilkins@tufts.edu. 4. Tufts University School of Medicine, Department of Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA 02186, USA. Electronic address: David.Landy@tufts.edu. 5. Tufts University School of Medicine, Department of Public Health and Community Medicine, 136 Harrison Avenue, Boston, MA 02186, USA. Electronic address: Thomas.Stopka@tufts.edu.
Abstract
BACKGROUND: New highly effective medications are available to treat the hepatitis C virus (HCV). However, little is known about HCV treatment knowledge and readiness among young people who inject drugs (PWID), or factors that may contribute to treatment uptake and adherence in this treatment era. PURPOSE: Using a framework for understanding healthcare utilization, we examined perspectives and experiences of young PWID tied to the HCV care continuum in Boston, Massachusetts, to inform future strategies. METHODS: We conducted 24 in-depth interviews with active and recent PWID aged 22-30 years living with HCV in Boston, February-August 2016. At the time of the interviews, no participants had been prescribed or had taken the new direct acting antivirals. We developed a codebook deductively from the interview guide and coded and analyzed the data into themes using a consensus-based process. RESULTS: The following five themes emerged, which captured PWID's knowledge of and experiences with HCV along the care continuum through social determinants of engagement in care, as well as illness level: (1) deservingness of HCV treatment and stigma, (2) dissatisfaction with provider interactions, (3) perceived lack of referral to treatment and care continuity, (4) disincentives around HCV treatment for PWID; and (5) perceived need for treatment. Young PWID living with HCV face unique barriers to HCV testing, counseling, and treatment. CONCLUSION: Breakdowns in the HCV care continuum may have adverse effects on HCV-treatment readiness and willingness. Improved public health and practice approaches are needed to address these barriers to effectively engage young PWID in care.
BACKGROUND: New highly effective medications are available to treat the hepatitis C virus (HCV). However, little is known about HCV treatment knowledge and readiness among young people who inject drugs (PWID), or factors that may contribute to treatment uptake and adherence in this treatment era. PURPOSE: Using a framework for understanding healthcare utilization, we examined perspectives and experiences of young PWID tied to the HCV care continuum in Boston, Massachusetts, to inform future strategies. METHODS: We conducted 24 in-depth interviews with active and recent PWID aged 22-30 years living with HCV in Boston, February-August 2016. At the time of the interviews, no participants had been prescribed or had taken the new direct acting antivirals. We developed a codebook deductively from the interview guide and coded and analyzed the data into themes using a consensus-based process. RESULTS: The following five themes emerged, which captured PWID's knowledge of and experiences with HCV along the care continuum through social determinants of engagement in care, as well as illness level: (1) deservingness of HCV treatment and stigma, (2) dissatisfaction with provider interactions, (3) perceived lack of referral to treatment and care continuity, (4) disincentives around HCV treatment for PWID; and (5) perceived need for treatment. Young PWID living with HCV face unique barriers to HCV testing, counseling, and treatment. CONCLUSION: Breakdowns in the HCV care continuum may have adverse effects on HCV-treatment readiness and willingness. Improved public health and practice approaches are needed to address these barriers to effectively engage young PWID in care.
Authors: Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi Journal: Drug Alcohol Depend Date: 2019-03-08 Impact factor: 4.492
Authors: Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta Journal: J Subst Abuse Treat Date: 2019-01-30
Authors: Kathleen M Ward; Sean D McCormick; Mark Sulkowski; Carl Latkin; Geetanjali Chander; Oluwaseun Falade-Nwulia Journal: Int J Drug Policy Date: 2020-11-04
Authors: Sabrina A Assoumou; Carlos R Sian; Christina M Gebel; Benjamin P Linas; Jeffrey H Samet; Judith A Bernstein Journal: Drug Alcohol Depend Date: 2021-01-11 Impact factor: 4.492
Authors: Gregg S Gonsalves; A David Paltiel; Thomas Thornhill; Suzan Iloglu; Alfred DeMaria; Kevin Cranston; R Monina Klevens; Rochelle P Walensky; Joshua L Warren Journal: Open Forum Infect Dis Date: 2021-03-15 Impact factor: 4.423